Oncology

An amended deal with Tasly positions AP Biosciences to license its innovative bispecific cancer therapy to global pharma giants, targeting a lucrative market.

As Precigen leaders prepare for a key investor chat, all eyes are on the explosive launch of PAPZIMEOS and the company's ambitious path to profitability.

Global CRO ChemPartner launches a new research site in Kent's Discovery Park, a major strategic push to accelerate drug development for European clients.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

Dr. Lisa G. Roth, a top oncologist and survivor, takes the helm at Hassenfeld, promising a new era of 'whole person' care for young cancer patients.

With a $150M war chest, OnKure pivots to a new class of PI3Kα inhibitors, aiming to revolutionize treatment for breast cancer and rare diseases.

A gene expression test is changing melanoma care by providing risk data beyond traditional staging, enabling more tailored treatment for patients.

Biocon merges its biosimilar and generics units, appointing 30-year veteran Shreehas Tambe as CEO to forge a new globally-scaled biopharma enterprise.

Biocon names 30-year veteran Shreehas Tambe as its new CEO, consolidating its biosimilar and generics arms to create a global biopharma powerhouse.

With critical data due in 2026 and a leaner financial strategy, Zentalis is advancing its targeted therapy for a hard-to-treat ovarian cancer.

A promising oral therapy for a rare, aggressive lung cancer is now under review in Europe, offering a new option for patients with limited treatments.

Eurofins Viracor's new assay delivers rapid insights into CAR T-cell performance, promising faster, more personalized decisions for cancer patients.

A new US-China partnership secures a vital supply of Lu-177, aiming to accelerate the development and delivery of targeted cancer therapies in China.

The company's B-cell cancer assay has achieved stringent IVDR certification, navigating a complex landscape and gaining a key edge in Europe's market.

Ono Pharma's application for ripretinib could bring a vital new treatment to Japanese GIST patients who have exhausted all other options.

As oncologists warn of supplement risks, one company founded by a doctor and caregiver aims to provide a safer, transparent path for cancer survivors.

The scientist behind PARP inhibitors is backing a new approach. Dr. Alan Ashworth's appointment at Leapfrog Bio signals a major push in precision oncology.

A new platform uses AI to turn complex genetic and lifestyle data into an immediate, actionable cancer prevention plan, shifting the paradigm of care.

A new collaboration aims to solve antibody reproducibility, promising to enhance diagnostic accuracy and accelerate the future of precision oncology.

Genomics leader IDT launches its first IVD-grade NGS tests for cancer, aiming to standardize diagnostics and accelerate precision medicine.